| product_name | (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride |
| CAS_number | 159209-62-2 |
| formula | C13H12N2O2·HCl |
| molar_mass | 280.71 g/mol |
| property_1 | Solid form |
| property_2 | Off-white color |
| property_3 | Solubility in water: slightly soluble |
| property_4 | Melting point: not specified |
| property_5 | Boiling point: not specified |
| property_6 | Storage conditions: room temperature |
| property_7 | Use in chemical synthesis |
| property_8 | Used in pharmaceutical applications |
| property_9 | Stable under recommended storage conditions |
| property_10 | Sensitive to moisture |
What is the role of (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) in pharmaceuticals?
(2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) is a compound that has shown promising results in the field of pharmaceutical research. It has been found to have potential therapeutic effects in treating various medical conditions due to its unique chemical structure and properties. This compound has the ability to interact with specific biological targets in the body, making it a valuable tool for developing new medications.
How does (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) work at the molecular level?
The molecular structure of (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) allows it to bind to certain receptors or enzymes in the body, modulating their activity and influencing biological processes. This interaction can lead to a variety of effects, such as altering signaling pathways, regulating gene expression, or inhibiting the function of specific proteins involved in disease pathways. By understanding how this compound works at the molecular level, researchers can better design drugs that target specific mechanisms of action.
What are the potential therapeutic applications of (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1)?
The therapeutic potential of (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) lies in its ability to target specific pathways or processes that are implicated in various diseases. This compound has shown promise in the treatment of conditions such as cancer, inflammatory disorders, neurodegenerative diseases, and metabolic disorders. By harnessing the unique properties of this molecule, researchers hope to develop new and more effective treatments for these challenging medical conditions.
What are the benefits of using (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) in drug discovery?
The use of (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) in drug discovery offers several advantages. This compound has a well-defined structure, making it easier to study its interactions with biological targets and predict its effects in the body. In addition, its chemical properties can be modified to enhance its efficacy, selectivity, and safety profile. By including this compound in the drug discovery process, researchers have access to a powerful tool for identifying new therapeutic agents and improving existing medications.
Can (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) be used in combination therapies?
Combination therapy, which involves using multiple drugs simultaneously to target different aspects of a disease, is a common approach in modern medicine. (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) can be a valuable component of combination therapies, as it can complement the effects of other drugs and enhance their overall efficacy. By combining this compound with other medications that have complementary mechanisms of action, researchers can potentially achieve synergistic effects and improve treatment outcomes for patients.
What are the challenges associated with using (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) in pharmaceutical development?
While (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) shows great promise in pharmaceutical development, there are several challenges that researchers may encounter. One challenge is optimizing the compound's pharmacokinetic properties, such as its absorption, distribution, metabolism, and excretion in the body. Additionally, ensuring the compound's selectivity for its intended target and minimizing off-target effects are critical considerations in drug development. Overcoming these challenges requires extensive research, testing, and collaboration among scientists and clinicians.
What are the future prospects for (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) in the pharmaceutical industry?
The future of (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) in the pharmaceutical industry looks promising. With ongoing research and development efforts focused on harnessing the compound's therapeutic potential, there is a strong possibility of discovering new applications for this molecule in treating a wide range of medical conditions. As our understanding of the compound's mechanisms of action continues to improve, it is likely to become an essential tool in drug discovery and development, leading to the creation of innovative medications that can benefit patients worldwide.
How can researchers and pharmaceutical companies collaborate to maximize the impact of (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) in healthcare?
Collaboration between researchers and pharmaceutical companies is crucial for maximizing the impact of (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) in healthcare. By sharing knowledge, resources, and expertise, scientists can accelerate the development of new medications that incorporate this compound and bring them to market more efficiently. Collaborations also enable the pooling of data from various studies, which can lead to new insights into the compound's mechanisms of action and potential applications. Ultimately, by working together, researchers and pharmaceutical companies can unlock the full therapeutic potential of (2E)-3-[4-(1H-Imidazol-1-ylmethyl)phenyl]acrylic acid hydrochloride (1:1) and improve patient outcomes in the healthcare industry.